4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

3 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

SCHEDULE 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

SCHEDULE 13G - Fortrea Holdings Inc. (0001965040) (Subject)

SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

SCHEDULE 13G - Fortrea Holdings Inc. (0001965040) (Subject)

DEFA14A - Fortrea Holdings Inc. (0001965040) (Filer)

DEF 14A - Fortrea Holdings Inc. (0001965040) (Filer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai

DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank

DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2025 financial results before the market opens on Monday, May 12, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.

For the three months and full-year ended December 31, 2024, from continuing operations: Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full yearGAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full yearAdjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full yearFourth-quarter book-to-bill ratio of 1.35x DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the fourth quarter and full year ended December 31, 2024. "Our intense focus on our customers' success and creating a

DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 3, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp

DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast l

For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of $(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of $(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of $504 million in the quarter using initial divestiture and securitization proceedsRevised full-year guidance DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contr

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast lin

For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings (loss) per share of $(0.91) and $(0.04), respectivelyBook-to-bill ratio of 1.11x, resulting in >1.2x book-to-bill for the trailing nine monthsPlanned divestiture of assets relating to the Endpoint Clinical and Patient Access businesses on track DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2024. "We are making solid progress toward o

DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced the appointment of Machelle Sanders to the Company's Board of Directors. Ms. Sanders has served as North Carolina's Secretary of Commerce since February 2021 and brings strong domain expertise from more than 30 years of operational and quality assurance roles in pharmaceutical and biotechnology companies. "Machelle's impressive background in life sciences and public service enables her to bring a unique and welcome perspective to our Board," said Tom Pike, chairman and CEO. "She is a highly respected leader, who understands our cu

DURHAM, N.C., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it convened last week the inaugural meeting of its Site Advisory Board, a collaboration between clinical research investigator sites ("sites") and industry leaders to create a better clinical trial experience for sites, patients and clinical study sponsors ("sponsors") by targeting changes in technology, operational planning and delivery, commercial terms and community engagement. Fortrea places sites and investigators at the forefront of clinical trial planning, leveraging their perspectives to drive changes that will improve the sp

DURHAM, N.C., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of John Doyle Dr.P.H., as its new President of Consulting. Doyle will serve on Fortrea's leadership team and lead a team of consultants and advisors with expertise that spans early development through lifecycle management. "Pharmaceutical and biotechnology innovators must constantly navigate complex and fast-changing business and regulatory environments to achieve their mission," said Tom Pike, chairman and chief executive officer of Fortrea. "John has extensive industry knowledge and distinctive technical skills that translate to

For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai

DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank

DURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a "Leader" for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea's top position was recognized in both pre-and post-approval PV operations in Everest Group's proprietary framework, which assesses market impact along with vision and capability. "Fortrea's mission is to bring life-changing treatments to patients faster, and we have translated our profound commitment to patients into recognized leadership in pharmacovigilance," said Mark Morais, c

DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2025 financial results before the market opens on Monday, May 12, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.

For the three months and full-year ended December 31, 2024, from continuing operations: Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full yearGAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full yearAdjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full yearFourth-quarter book-to-bill ratio of 1.35x DURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the fourth quarter and full year ended December 31, 2024. "Our intense focus on our customers' success and creating a

DURHAM, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that it will appoint Erin L. Russell, a financial and healthcare executive, as a new independent member of the Company's Board of Directors (the "Board") effective immediately prior to the next regularly scheduled meeting of the Board. Ms. Russell is being appointed in connection with a cooperation agreement (the "Agreement") between Fortrea and Starboard Value LP (together with its affiliates, "Starboard"), an investment firm that owns approximately 5.4% of the Company's outstanding common stock. "We are pleased to have reached a constructive agree

DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie

DURHAM, N.C., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 3, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings

SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Citi Global Healthcare Conference on Wednesday, December 4, 2024 at 1:45 pm ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the event. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmac